Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Lutavit A/D3 1000/200 NXT provides a combination of vitamin A and vitamin D3 in one formulation
This new suite of products demonstrates Nouryon’s leadership in cleaning ingredient solutions
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
These findings follow positive Phase 3 results presented earlier this year
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Subscribe To Our Newsletter & Stay Updated